Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.

Conclusions: Monoclonal antibodies inhibiting CGRP are effective in migraine prophylaxis with minimal adverse effects. Targeting CGRP is a novel clinical strategy in managing migraine. PMID: 32019317 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32019317?dopt=Abstract

Source: The Annals of Pharmacotherapy - February 4, 2020 Category: Drugs & Pharmacology Authors: Arca K, Reynolds J, Sands KA, Shiue HJ Tags: Ann Pharmacother Source Type: research